L
Logos Global Management, L.P.
+ HoldingFTH
+24.41%
3M Return
$34.510
+1.832 (+5.31%)Al cierre
Loading chart…
- High
- 34.700
- Open
- 33.680
- VWAP
- 34.30
- Vol
- 276.71K
- Mkt Cap
- —
- Low
- 33.680
- Amount
- 9.49M
- EV/EBITDA, TTM
- 0.00
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
AI analysis of Faeth Therapeutics, Inc (FTH)
buyFaeth Therapeutics appears to be a good buy right now, with a current price of $33.84 and a strong 5-day change of +5.75%. The RSI is at 63.079, suggesting bullish momentum. Additionally, analysts project a price target of $56, which represents a potential upside of approximately 65% from the current price. However, the main risk is the significant net loss reported for Q1 2026, which was -$170.2 million, indicating ongoing financial challenges that investors should monitor closely.
Métricas de valoración
The current forward P/E ratio for Faeth Therapeutics, Inc (FTH) is 0.00, compared to its 5-year average forward P/E of .
Whales holding FTH
Cronología de eventos
Noticias
5.008-28NewsfilterFaeth Therapeutics Grants Stock Options to New Employees
- 8.508-17Newsfilter
Faeth Receives FDA Fast Track Designation for PIKTOR
- 5.008-14Newsfilter
Faeth Therapeutics Appoints New Executives to Enhance Operations and Investor Relations
9.508-10NASDAQ.COMFaeth Therapeutics Shares Surge 18% on Pipeline Update
- 8.508-07Newsfilter
Faeth Therapeutics to Present PIKTOR Data at 2026 Cancer Summit
FTH FAQ — answered by Alphio AI
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib. It operates in the Healthcare sector.
Faeth Therapeutics appears to be a good buy right now, with a current price of $33.84 and a strong 5-day change of +5.75%. The RSI is at 63.079, suggesting bullish momentum. Additionally, analysts project a price target of $56, which represents a potential upside of approximately 65% from the current price. However, the main risk is the significant net loss reported for Q1 2026, which was -$170.2 million, indicating ongoing financial challenges that investors should monitor closely.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.